M Stojsić
Biographic Data
| ID | 8264280 |
|---|---|
| NAME | M Stojsić |
| GIVEN NAMES | M |
| FAMILY NAME | Stojsić |
| SIGNATURE | STOJSIĆ M |
| AFFILIATIONS | University of Novi Sad |
| ORCID | 0000-0002-0890-9732 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
TPMT and HLA-DQ Allelic Variants in Relation to Drug Response, Safety and Need for Therapy Optimization in Pediatric Inflammatory Bowel Disease
Prior to the initiation of azathioprine therapy, TPMT genotyping should be performed to prevent adverse effects and ensure optimal drug dosing. Identification of the HLA-DQA105 and HLA-DQA101 alleles plays an important role in the planning of biological therapy regimens, including decisions on dose escalation or interval shortening
No prominent works on this page.
TPMT and HLA-DQ Allelic Variants in Relation to Drug Response, Safety and Need for Therapy Optimization in Pediatric Inflammatory Bowel Disease
Prior to the initiation of azathioprine therapy, TPMT genotyping should be performed to prevent adverse effects and ensure optimal drug dosing. Identification of the HLA-DQA105 and HLA-DQA101 alleles plays an important role in the planning of biological therapy regimens, including decisions on dose escalation or interval shortening
Adverse effect (1 work) · Allele (1 work) · Azathioprine (1 work) · Disease (1 work) · Drug (1 work) · Genotyping (1 work) · Immunodeficiency and Autoimmune Disorders (1 work) · Inflammatory Bowel Disease (1 work) · Pharmaceutical studies and practices (1 work) · Pharmacogenetics (1 work)